

ADH and hyponatremia with theophylline. *Ann Pharmacother*, 2002; 36: 1180–1182.

12. Verghese C, de Leon J, Josiassen RC. Problems and progress in the diagnosis and treatment of polydipsia and hyponatremia. *Schizophr Bull*. 1996; 22: 455–464.

13. Evenson RC, Jos CJ, Mallya AR. Prevalence of polydipsia among public psychiatric patients. *Psychol Rep*. 1987; 60: 803–807.

14. Tan ECK, Lexomboon D, Sandborgh-Englund G, Haasum Y, Johnell K. Medications That Cause Dry Mouth As an Adverse Effect in Older People: A Systematic Review and Meta-analysis. *J Am Geriatr Soc*, 2018; 66(1): 76–84.

15. SPC.

16. Cersosimo MG, Raina GB, Calandra CR, Pellene A, Gutiérrez C, Micheli FE, Benarroch EE., Dry mouth: an overlooked autonomic symptom of Parkinson's disease., *J Parkinsons, Dis*. 2011; 1(2): 169–173.

17. Movig KLL, Leufkens HGM, Lenderink AW, Egberts ACG. Serotonergic antidepressants associated with an increased risk for hyponatremia in the elderly. *Eur J Clin Pharmacol*, 2002; 58: 143–148.

18. Farmand S, Lindh J, Calissendorff J. Differences in associations of antidepressants and hospitalization due to hypo-

natremia, *Am J Med*, 2018; 131(1): 56–63.

19. Gandhi S, Shariff SZ, Al-Jaishi A, Reiss JP, Mamdani MM, Hackam DG, Li L, McArthur E, Weir MA, Garg AX. Second-generation antidepressants and hyponatremia risk: a population-based cohort study of older adults. *Am J Kidney Dis*, 2017; 69: 87–96.

20. Rose BD, Post TW. *Clinical Physiology of Acid-Base and Electrolyte Disorders*, ed 5. New York, McGraw-Hill, 2001; 702.

21. Mogi T, Yoshono A, Ikemoto G, Nomura S. Mirtazapine as an alternative for selective serotonin reuptake inhibitor induced syndrome of inappropriate secretion of antidiuretic hormone. *Pharmacopsychiatry*, 2007; 40: 129–131.

22. Cheah CY, Ladhams B, Fegan PG. Mirtazapine associated with profound hyponatremia: two case reports. *Am J Geriatr Pharmacother*, 2008; 6: 91–95.

23. Lien YH. Antidepressants and hyponatremia, *Am J Med*, 2018; 131(1): 7–8.

24. NazAli S, Bazzano LA. Hyponatremia in association with second-generation antipsychotics: a systematic review of case reports, *Ochsner Journal*, 2018; 18: 230–235.

25. Van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: A review. *Epilepsia* 35; 181–188, 1994.

26. Kuz GM, Manssourian A. Carbamazepine-induced hyponatremia: Assessment of risk factor. *Ann Pharmacother*, 2005; 39: 1943–1946.

27. Bressler RB, Huston DP. Water intoxication following moderate-dose intravenous cyclophosphamide. *Arch Intern Med* 1985; 145: 548–549.

28. Pham L, Shaer AJ, Marnejon T. Hyponatremia- a rare but serious complication of amiodarone: a case report and review of the literature, *Case rep Nephrol urol*, 2013; 3: 46–50.

29. Brewster UC, Perazella MA: proton pump inhibitors and the kidney: Critical review. *Clin Nephrol*, 2007; 72: 65–72.

30. Holden R, Jackson MA. Near-fatal hyponatremic coma due to vasopressin over-secretion after „extasy“ (3,4–methylendioxyamfetamine). *Lancet*, 1996; 347: 1052.

31. Peters NA, Farrel LB, Smith JP. Hyperosmolar therapy for the treatment of cerebral edema, *US Pharm*, 2018; 43(1): 8–11.

32. Fandino W. Understanding the physiological changes induced by mannitol: From the theory to the clinical practice in neuroanaesthesia, *J Neuroanaesthesiol Crit Care*, 2017; 4: 138–146.

33. Nomani AZ1, Nabi Z, Rashid H, Janjua J, Nomani H, Majeed A, Chaudry SR, Mazhar AS. Osmotic nephrosis with mannitol: Review article. *Ren Fail*, 2014; 36: 1169–1176.